Inactive Instrument

JHL Biotech, Inc.

6540

KYG7863U1076

JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis

December 20, 2017 at 01:29 pm EST

JHL Biotech announced that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for its proposed dornase alfa biosimilar, JHL1922, to improve pulmonary function in cystic fibrosis patients.

Latest news about JHL Biotech, Inc.

Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.	22-05-09	CI
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar	20-05-18	CI
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma	18-12-27	CI
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer	18-10-15	CI
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer	18-08-09	CI
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar	18-07-09	CI
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma	18-07-05	CI
JHL Biotech, Inc. Appoints Ellis Chu as Chief Financial Officer	18-06-13	CI
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors	18-05-14	CI
JHL Biotech Seeks Financing	18-03-30	CI
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application	18-02-22	CI
JHL Biotech, Inc.(GTSM:6540) dropped from S&P Global BMI Index	18-02-12	CI
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.	18-02-05	CI
JHL Biotech, Inc. announced that it expects to receive $150 million in funding	18-01-15	CI
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis	17-12-20	CI
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers	17-12-20	CI
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials	17-04-04	CI
JHL Doses First Patient In JHL1101 Phase I European Trial	17-03-29	CI
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China	16-12-05	CI
JHL Biotech, Inc. announced that it expects to receive TWD 2.55 billion in funding from Sanofi	16-12-04	CI
JHL Biotech, Inc. announced that it has received TWD 2.55736 million in funding	16-12-01	CI
JHL Biotech Announces Executive Appointments	16-10-31	CI
JHL Biotech : GE brings off-the-shelf biotech drug factories to Ireland	16-09-19	RE
JHL Biotech, Inc.(GTSM:6540) added to S&P Global BMI Index	16-09-19	CI
JHL Biotech, Inc. Enters into A Contract Manufacturing Agreement with BeiGene, Ltd	16-06-13	CI

Chart JHL Biotech, Inc.

Duration

Period

More charts

Company Profile

JHL BIOTECH, INC. is a Taiwan-based company principally engaged in development and manufacturing of biopharmaceuticals. The Company provides cell line cloning, process development, and manufacturing capabilities and services to emerging and established biopharmaceutical companies seeking to collaboratively develop, manufacture and commercialize biologics.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-3.79%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
INCYTE CORPORATION	-14.38%	12.07B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B

Biopharmaceuticals